Moreover, several studies have shown that APOA1 levels can be considered a biomarker with reduced plasma levels in patients with early stage ovarian cancer compared with normal individuals (Clarke et al., 2011; Kim et al., 2012; Kozak et al., 2003; Moore et al., 2006). The gene discussed is APOA1; the disease is ovarian carcinoma.